Literature DB >> 15576055

Implications of exercise training in mtDNA defects--use it or lose it?

Tanja Taivassalo1, Ronald G Haller.   

Abstract

Whether regular exercise is beneficial or should be avoided is a question currently unsettled in patients with heteroplasmic mitochondrial DNA (mtDNA) disorders of skeletal muscle. Deleterious effects of habitual physical inactivity superimposed upon impaired mitochondrial oxidative phosphorylation may contribute to varying degrees of exercise intolerance in these patients. Endurance exercise training is widely known to improve exercise capacity in healthy subjects and various chronic-disease patient populations. Although we have shown that beneficial physiological and biochemical responses to training increase exercise tolerance in patients with mtDNA defects, knowledge of the muscle adaptive response to endurance training within the setting of mitochondrial heteroplasmy remains limited. In order to determine advisability of endurance training as therapy, it remains to be established whether potential endurance training-induced increases in mutant mtDNA levels may be offset by increases in absolute wild-type mtDNA levels, and whether chronic inactivity leads to a selective down-regulation of wild-type mtDNA. Resistance training utilizes a different adaptive exercise approach to induce the transfer of normal mitochondrial templates from satellite cells to mature muscle fibers of patients with sporadic mtDNA disorders. The efficacy and safety of this approach needs to be further established. Our current inability to clearly advise patients to "use it or lose it" underscores the immediate urgency of studying the effects of exercise on skeletal muscle of patients with heteroplasmic mtDNA defects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15576055     DOI: 10.1016/j.bbabio.2004.09.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

1.  Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease.

Authors:  Maria Pilar Bayona-Bafaluy; Bas Blits; Brendan J Battersby; Eric A Shoubridge; Carlos T Moraes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-22       Impact factor: 11.205

Review 2.  Young-onset dementia.

Authors:  Dulanji K Kuruppu; Brandy R Matthews
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

3.  Arginine and citrulline for the treatment of MELAS syndrome.

Authors:  Ayman W El-Hattab; Mohammed Almannai; Fernando Scaglia
Journal:  J Inborn Errors Metab Screen       Date:  2017-03-24

Review 4.  Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases.

Authors:  Martine Uittenbogaard; Anne Chiaramello
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  Prolonged exercise testing in two children with a mild Multiple Acyl-CoA-Dehydrogenase deficiency.

Authors:  T Takken; Jwh Custers; G Visser; L Dorland; Pjm Helders; Tj de Koning
Journal:  Nutr Metab (Lond)       Date:  2005-05-20       Impact factor: 4.169

6.  Altered skeletal muscle (mitochondrial) properties in patients with mitochondrial DNA single deletion myopathy.

Authors:  Saskia Maria Gehrig; Violeta Mihaylova; Sebastian Frese; Sandro Manuel Mueller; Maria Ligon-Auer; Christina M Spengler; Jens A Petersen; Carsten Lundby; Hans H Jung
Journal:  Orphanet J Rare Dis       Date:  2016-07-29       Impact factor: 4.123

Review 7.  Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients.

Authors:  Jolanta Malyszko; Stefan D Anker
Journal:  Clin Kidney J       Date:  2017-11-28

8.  Mitochondrial DNA deletion and sarcopenia.

Authors:  Vallabh O Shah; John Scariano; Debra Waters; Clifford Qualls; Marilee Morgan; Gavin Pickett; Chuck Gasparovic; Karol Dokladny; Pope Moseley; Dominic S C Raj
Journal:  Genet Med       Date:  2009-03       Impact factor: 8.822

9.  Mitochondrial DNA deletions in muscle satellite cells: implications for therapies.

Authors:  Sally Spendiff; Mojgan Reza; Julie L Murphy; Grainne Gorman; Emma L Blakely; Robert W Taylor; Rita Horvath; Georgia Campbell; Jane Newman; Hanns Lochmüller; Doug M Turnbull
Journal:  Hum Mol Genet       Date:  2013-07-11       Impact factor: 6.150

Review 10.  A Critical Assessment of the Therapeutic Potential of Resveratrol Supplements for Treating Mitochondrial Disorders.

Authors:  Boel De Paepe; Rudy Van Coster
Journal:  Nutrients       Date:  2017-09-14       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.